跳至主要内容
临床试验/NCT00893854
NCT00893854Unknown1 期

The Comparison Between the Therapeutic Affect of Intravitreal Diclophenac and Triamcinolone in Persistent Uveitic Cystoids Macular Edema

Shahid Beheshti University of Medical Sciences1 个研究点 分布在 1 个国家开始时间: 2009年5月6日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
试验地点
1

研究概览

简要总结

Cystoids macular edema (CME) is one of the most common causes of low vision due to uveitis. The treatment for reducing the intra-ocular inflammation can decrease the macular edema. In some patients, CME persists even after inflammation control, and additional treatment is needed for better vision. Oral steroid, periocular and intravitreal Triamcinolone are the principles in treatment, but some complications like cataracts and increased ocular pressure have been seen. Diclophenac is a non-steroid anti-inflammatory drug that improves the vision and decreases the macular thickness by slowing down the prostaglandin E2 (PGE2) ending in vascular endothelial growth factor (VEGF) inhibition. In this study, the investigators are going to compare the therapeutic affect of intravitreal Diclophenac and Triamcinolone in persistent uveitic cystoids macular edema. Since diclophenac is a cheap and accessible drug in all curative centers it could be applied instead of Triamcinolone.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

性别
All
接受健康志愿者

入选标准

  • cystoids macular edema which is diagnosed by OCT and flurocein angiography
  • 5/200 < Visual acuity < 20/50
  • resistance to routine treatment (oral treatment, periocular injection)

排除标准

  • history of retinal disease cause macular edema like diabetes
  • arterial occlusion
  • monocular patients
  • patients candidate for intra-ocular operation
  • history of glaucoma or ocular hypertension
  • any cataract that would interfere with OCT

研究组 & 干预措施

Diclophenac

Experimental

干预措施: Diclophenac (Drug)

Triamcinolone

Experimental

干预措施: Triamcinolone (Drug)

研究者

研究点 (1)

Loading locations...

相似试验